Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia

Feifei Wang, Mingzhu Liu, Yi Sui, Qing Cao, Bo Yan, Meiling Jin, Xi MoOncology 2016 · DOI

Abstract

Acute promyelocytic leukemia (APL) treatment often relies on arsenic trioxide (As₂O₃), which induces apoptosis via endoplasmic reticulum (ER) stress. This study investigates the role of SUMO-specific protease 1 (SENP1) in this process. Using NB4 cells, researchers demonstrated that while SENP1 deficiency does not affect spontaneous apoptosis or differentiation, it significantly sensitizes cells to As₂O₃-induced death. Mechanistically, SENP1 knockdown leads to the accumulation of SUMOylated XBP1, suppressing the expression of survival-related target genes like Erdj4 and Sec61a. These findings highlight SENP1 as a potential therapeutic target to enhance the efficacy of APL treatments.

Introduction

Acute Promyelocytic Leukemia (APL) is a subtype of leukemia characterized by the fusion protein PML-RARα. While the combination of All-Trans Retinoic Acid (ATRA) and arsenic trioxide (As₂O₃) has revolutionized APL therapy, resistance remains a clinical challenge. Arsenic trioxide works by triggering the Unfolded Protein Response (UPR) due to ER stress. Central to this response is XBP1, a transcription factor whose activity is regulated by SUMOylation. This study explores how SENP1, a de-SUMOylating enzyme, modulates XBP1 activity and influences the apoptotic response to arsenic.

Methodology

The study employed the human APL cell line NB4. SENP1 expression was silenced using retroviral-delivered siRNA. The efficiency of this knockdown was verified via RT-qPCR. Apoptosis was quantified using Annexin V/PI staining followed by flow cytometry. Cell differentiation was assessed by measuring the expression of the surface marker CD11b. To investigate the molecular mechanism, the researchers used immunoprecipitation to detect SUMOylated XBP1 and RT-qPCR to measure the mRNA levels of XBP1 target genes (Erdj4, Sec61a) and ER stress markers (GRP78, GADD153).

Results

SENP1 Knockdown and Baseline Cellular Effects

Initial experiments confirmed that SENP1 mRNA levels were significantly reduced following siRNA transfection. Crucially, the deficiency of SENP1 alone did not trigger spontaneous apoptosis or induce cell differentiation in the absence of other stimuli. As shown in the flow cytometry data, the baseline apoptosis rates and ATRA-induced CD11b expression remained largely unchanged between control and SENP1-knockdown groups.

Figure 1: SENP1 knockdown efficiency and its impact on spontaneous apoptosis and differentiation. (A) mRNA levels confirming knockdown. (B) Baseline apoptosis rates. (C) CD11b expression levels indicating no significant effect on differentiation.

Sensitization to Arsenic Trioxide

The role of SENP1 became evident upon treatment with As₂O₃. In control cells, arsenic treatment resulted in an apoptosis rate of approximately 37%. However, in SENP1-deficient cells, this rate increased dramatically to 66%. This indicates that SENP1 acts as a survival factor specifically during periods of drug-induced stress.

The Molecular Mechanism: XBP1 and ER Stress

The researchers found that SENP1 deficiency leads to an accumulation of SUMOylated (inactive) XBP1. Under normal conditions, SENP1 de-SUMOylates XBP1, allowing it to activate target genes like Erdj4 and Sec61a which help the cell manage ER stress. Without SENP1, these protective genes are downregulated, and the ER stress induced by arsenic becomes overwhelming, leading to the upregulation of pro-apoptotic markers like GADD153 and subsequent cell death.

Discussion and Conclusion

This study identifies the SENP1/XBP1 axis as a critical regulator of the ER stress response in APL cells. By maintaining XBP1 in its active, de-SUMOylated state, SENP1 helps leukemia cells survive the proteotoxic stress caused by arsenic trioxide. Inhibiting SENP1 could therefore represent a potent strategy to sensitize APL cells to existing therapies. Future research should focus on validating these findings in in vivo models and exploring the potential of SENP1 as a clinical biomarker for treatment response.

Summary updated

Abstract

Small ubiquitin-like modifier (SUMO)/sentrin-specific protease 1 (SENP1), a member of the SENP family, is highly expressed in several neoplastic tissues. However, the effect of SENP1 in acute promyelocytic leukemia (APL) has not been elucidated. In the present study, it was observed that SENP1 deficiency had no effect on the spontaneous apoptosis or differentiation of NB4 cells. Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) could induce the upregulation of endoplasmic reticulum (ER) stress, resulting in the apoptosis of NB4 cells. Additionally, knockdown of SENP1 significantly increased As<sub>2</sub>O<sub>3</sub>-induced apoptosis in NB4 cells transfected with small interfering RNA targeting SENP1. SENP1 deficiency also increased the accumulation of SUMOylated X-box binding protein 1 (XBP1), which was accompanied by the downregulation of the messenger RNA expression and transcriptional activity of the XBP1 target genes endoplasmic reticulum-localized DnaJ 4 and Sec61a, which were involved in ER stress and closely linked to the apoptosis of NB4 cells. Taken together, these results revealed that the specific de-SUMOylation activity of SENP1 for XBP1 was involved in the ER stress-mediated apoptosis caused by As<sub>2</sub>O<sub>3</sub> treatment in NB4 cells, thus providing insight into potential therapeutic targets for APL treatment via manipulating XBP1 signaling during ER stress by targeting SENP1.
BibTeX
@inproceedings{wang2016deficiency,
  author = {Feifei Wang and Mingzhu Liu and Yi Sui and Qing Cao and Bo Yan and Meiling Jin and Xi Mo},
  title = {{Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia}},
  booktitle = {Oncology},
  year = {2016},
  doi = {10.3892/ol.2016.5162},
}
Figure